NCT01414075View on ClinicalTrials.gov

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 21, 2011

Primary Completion Date

January 10, 2013

Study Completion Date

January 10, 2013

Conditions
DialysisAnemia
Interventions
DRUG

Roxadustat

Tiered, weight-based dosing per schedule specified in the arm.

DRUG

Oral Iron

Administered per oral dose and schedule specified in the arm.

DRUG

IV Iron

Administered per IV dose and schedule specified in the arm.

Trial Locations (7)

Unknown

Northridge

Yuba City

Detroit

Hong Kong

Moscow

Saint Petersburg

Singapore

Sponsors

Lead Sponsor

FibroGen

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

FibroGen

INDUSTRY

NCT01414075 - Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment | Biotech Hunter | Biotech Hunter